今日熱門話題

ar/ng/dk/GOG/Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

|

You are leaving and open the following URL" of about "be" news

www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02175-9/fulltext


Continue Opne >

be: ar/ng/dk/GOG/Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial


More be news:


About be

from

be, ar/ng/dk/GOG/Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial 2022 be

ar/ng/dk/GOG/Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

Choose Your Country or Region


Back to Top



Copyright © 2020-2021 loohk.com. All Rights Reserved.